Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
lame:	Name:
Vard:	NHI:
enalidomide	
INITIATION – Plasma cell dyscrasia	
Prerequisites (tick boxes where appropriate)	
O Prescribed by, or recommended by any relevant practitione NZ Hospital.	er, or in accordance with a protocol or guideline that has been endorsed by the Health
O Patient has plasma cell dyscrasia, not including Wald	denström macroglobulinaemia, requiring treatment
O Patient is not refractory to prior lenalidomide use	
INITIATION – Myelodysplastic syndrome Re-assessment required after 6 months	
Prerequisites (tick boxes where appropriate)	
O Prescribed by, or recommended by any relevant practitione NZ Hospital.	er, or in accordance with a protocol or guideline that has been endorsed by the Health
	c syndrome (based on IPSS or an IPSS-R score of less than 3.5) associated with
O Patient has transfusion-dependent anaemia	
CONTINUESTICAL Manufaction and design and design	
CONTINUATION – Myelodysplastic syndrome Re-assessment required after 12 months	
Prerequisites (tick boxes where appropriate)	
O Prescribed by, or recommended by any relevant practitione NZ Hospital.	er, or in accordance with a protocol or guideline that has been endorsed by the Health
O Patient has not needed a transfusion in the last 4 mo	enths
O No evidence of disease progression	

I confirm that the above details are correct:

Signed: ...... Date: ......